47 completed, 42 terminated, 30 active not recruiting, 25 unknown. 183 Phase 2, 63 Phase 1.
Follow avelumab: new trials by email Literature Review of avelumab trials Research Report on avelumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer AlloStim, Bavencio - Metastatic Colorectal Cancer | Phase 2 | Withdrawn | Mirror Biologics, Inc. | 2026-11-01 | 2025-10-21 | |
| Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma Avelumab 800 mg flat-dose IV - Urothelial Carcinoma | Phase 2 | Not yet recruiting | Gruppo Oncologico Italiano di Ricerca Clinica | 144 | 2026-06-01 | 2026-03-10 |
| DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma Avelumab, enfortumab vedotin - Penile Squamous Cell Carcinoma (PSCC) | Phase 2 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 25 | 2025-12-16 | 2026-10-13 |
| Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC Avelumab 10 mg/kg, Screening, Best Supportive Care (BSC) - Upper Tract Urothelial Carcinoma | Phase 2 | Recruiting | Samsung Medical Center | 48 | 2025-09-16 | 2025-11-06 |
| Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab - Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Ariceum Therapeutics GmbH | 2 | 2025-07-01 | 2026-02-05 |
| Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer copanlisib, Avelumab - Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Withdrawn | VA Office of Research and Development | 2025-06-02 | 2025-06-15 | |
| Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19. Cetuximab/avelumab - Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer | Phase 2 | Recruiting | Gruppo Oncologico del Nord-Ovest | 67 | 2025-02-20 | 2025-03-14 |
| Avelumab and M1774 in ARID1A-mutated Endometrial Cancer Avelumab, M1774 - Endometrial Cancer, ARID1A Gene Mutation | Phase 2 | Active not recruiting | Panagiotis Konstantinopoulos, MD, PhD | 8 | 2024-11-14 | 2026-10-26 |
| Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder) Avelumab, Tuvusertib - Urothelial Carcinoma | Phase 2 | Withdrawn | EMD Serono Research & Development Institute, Inc. | 2024-08-16 | 2024-09-27 | |
| Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) Lurbinectedin, Avelumab - Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract | Phase 2 | Recruiting | National Cancer Institute (NCI) | 45 | 2024-06-13 | 2026-10-16 |
| Avelumab, Palbociclib and Axitinib in Advanced RCC Axitinib, Palbociclib, Avelumab - Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Withdrawn | Bradley A. McGregor, MD | 2024-05-31 | 2023-09-07 | |
| Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial Avelumab, Biopsy Procedure, Biospecimen Collection - Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 50 | 2024-05-21 | 2026-07-31 |
| Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Zelenectide pevedotin, Pembrolizumab, Gemcitabine + cisplatin Or carboplatin - Metastatic Urothelial Cancer | Phase 2 | Active not recruiting | BicycleTx Limited | 375 | 2024-01-24 | 2026-10-29 |
| A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer Avelumab, Aspirin, Lansoprazole - Breast Cancer | Phase 2 | Withdrawn | The Christie NHS Foundation Trust | 2023-12-01 | 2025-12-08 | |
| Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI CP-506, Carboplatin, Immune checkpoint inhibitor - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Recruiting | Maastricht University Medical Center | 126 | 2023-05-30 | 2025-10-07 |
| Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin - Metastatic Cancer, Urothelial Carcinoma | Phase 2 | Withdrawn | AdventHealth | 2023-05-08 | 2024-08-01 | |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial Avelumab, Axitinib, Biospecimen Collection - Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 240 | 2023-02-01 | 2026-10-23 |
| Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma Avelumab and Pepinemab - Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Vaccinex Inc. | 48 | 2022-12-10 | 2025-05-21 |
| Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer Avelumab - Urothelial Carcinoma | Phase 2 | Recruiting | Erasmus Medical Center | 64 | 2022-12-01 | 2023-09-08 |
| Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma Axitinib, Avelumab, Bavituximab - Hepatocellular Carcinoma | Phase 2 | Terminated | University of Texas Southwestern Medical Center | 1 | 2022-11-04 | 2023-05-03 |
Showing 20 of 183. Sign in to see all of them.
Urinary Bladder Neoplasms (20) · Carcinoma, Non-Small-Cell Lung (18) · Carcinoma, Merkel Cell (17) · Carcinoma, Transitional Cell (16) · Colorectal Neoplasms (13) · Breast Neoplasms (12) · Neoplasm Metastasis (12) · Carcinoma, Renal Cell (10) · Neoplasms (10) · Pancreatic Neoplasms (7) · Squamous Cell Carcinoma of Head and Neck (7) · Triple Negative Breast Neoplasms (7) · Stomach Neoplasms (6) · Carcinoma, Hepatocellular (5) · Head and Neck Neoplasms (5)
ImmunityBio, Inc. (23) · National Cancer Institute (NCI) (9) · Pfizer (9) · M.D. Anderson Cancer Center (7) · Gruppo Oncologico del Nord-Ovest (5) · Memorial Sloan Kettering Cancer Center (4) · Dana-Farber Cancer Institute (3) · EMD Serono Research & Development Institute, Inc. (3) · Fred Hutchinson Cancer Center (3) · Samsung Medical Center (3) · Universitair Ziekenhuis Brussel (3) · 4SC AG (2) · AHS Cancer Control Alberta (2) · Consorzio Oncotech (2) · Johannes Gutenberg University Mainz (2)
United States (97) · Italy (22) · France (20) · Spain (20) · South Korea (17) · Australia (16) · Canada (16) · Belgium (14) · Germany (13) · United Kingdom (13) · Netherlands (7) · Hungary (6) · Japan (5) · Poland (5) · Taiwan (5)
Anne Armstrong (2) · Matthias M Weber, MD (2) · Panagiotis Konstantinopoulos, MD, PhD (2) · Simron Singh (2) · Aaron Goldberg, MD, PhD (1) · Adrienne Waks, MD, PhD (1) · Alexander Stein, PD Dr. (1) · Amishi Y Shah (1) · Amishi Y Shah, MD (1) · Andrea B Apolo, M.D. (1)
PMID 35504244, PMID 19269895, PMID 27592805, PMID 29273043, PMID 29347993, PMID 29512061, PMID 29566106, PMID 29914528, PMID 31023100, PMID 31053174, PMID 31401903, PMID 31538815, PMID 31553054, PMID 32375680, PMID 32379297, PMID 32414862, PMID 32430019, PMID 32472503, PMID 32508818, PMID 32620210, PMID 32620211, PMID 32766875, PMID 32938212, PMID 33139266, PMID 33219092, PMID 33820783, PMID 33892407, PMID 33929895, PMID 34001010, PMID 34301810, PMID 34315821, PMID 34347542, PMID 34382998, PMID 34393061, PMID 34462327, PMID 34543871, PMID 34604752, PMID 34815354, PMID 34856936, PMID 34921021, PMID 35292724, PMID 35292802, PMID 35307972, PMID 35442137, PMID 35832541, PMID 35900726, PMID 36083313, PMID 36210487, PMID 36394849, PMID 36394867
2017 (10), 2018 (9), 2016 (5), 2019 (3), 2023 (3), P30CA015704 (3), 2014 (2), 2015 (2), 2025 (1), K24CA139052 (1), P01CA225517 (1), P30CA016672 (1), P30CA138292 (1), R01CA176841 (1), R01CA181450 (1)